Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GH Research PLC (GHRS : NSDQ)

• Company Description    GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $12.76 Daily Weekly Monthly 20 Day Moving Average: 362,002 shares Shares Outstanding: 52.03 (millions) Market Capitalization: $663.88 (millions) Beta: 0.97 52 Week High: $20.50 52 Week Low: $6.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.27% -9.11% 12 Week -8.73% -13.31% Year To Date 82.29% 60.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL JOSHUA DAWSON HOUSE DAWSON STREET - DUBLIN,L2 D02 RY95 IRL ph: 353-1437-8334 fax: - investors@ghres.com http://www.ghres.com

• General Corporate Information    Officers Velichka Valcheva - Chief Executive Officer Florian Schonharting - Chairman and Director Michael Forer - Vice Chairman Aaron Cameron - Chief Operating Officer Julie Ryan - Vice President Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G3855L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 52.03 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $663.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: 21.05% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -16.71 03/31/25 - -19.20 ROA 09/30/25 - - 06/30/25 - -16.06 03/31/25 - -18.40 Current Ratio 09/30/25 - - 06/30/25 - 29.49 03/31/25 - 29.71 Quick Ratio 09/30/25 - - 06/30/25 - 29.49 03/31/25 - 29.71 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 5.83 03/31/25 - 5.96 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.09 03/31/25 - 0.10

Powered by Zacks Investment Research ©